Study of Daclatasvir-based Therapy in Chinese Participants With Chronic Hepatitis C (CHC)

Bristol-Myers Squibb (BMS)

Status: Terminated

Conditions: Chronic Hepatitis C

Study type: Observational

Funder types: Industry

Identifiers

NCT03500562

AI444-396

Details and patient eligibility

About

Study is a non-interventional, prospective, multicenter post marketing surveillance study to determine the safety of daclatasvir based therapy

Enrollment: 3 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Participants 18 years of age and older
• Participants with Chronic Hepatitis C virus (CHC) who are eligible for treatment with branded DCV-based therapy as indicated in the locally approved label

Exclusion criteria

• Participants under the age of 18

Other protocol defined inclusion/exclusion criteria could apply

Trial design

3 participants in 1 patient group

HCV participant population in China